ClinicalTrials.govpublic full text
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
chronic heart failure with reduced systolic function, heart failure, dapagliflozin, sodium-glucose co-transporter-2 (sglt-2) inhibitors, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 836393
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.